NCT05593588View on ClinicalTrials.gov

Senolytics Treatment of Interstitial Lung Disease in Common Variable Immunodeficiency

PHASE2Enrolling by invitationINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

April 12, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions
Common Variable ImmunodeficiencyInterstitial Lung Disease Due to Systemic Disease
Interventions
DRUG

Fisetin

20 mg per kilogram (kg) of body weight supplied in 100 mg capsules and administered orally on days 0, 1, 28, and 29

DRUG

Placebo

Looks exactly like the study drug, but it contains no active ingredient. Administered orally on days 0, 1, 28 and 29

Trial Locations (1)

55905

Mayo Clinic in Rochester, Rochester

All Listed Sponsors
lead

Avni Joshi

OTHER